Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2017

01-02-2017 | Editorial

Growth hormone and the heart in growth hormone deficiency—what have we learned so far?

Authors: Jörgen Isgaard, Antonio Cittadini

Published in: Endocrine | Issue 2/2017

Login to get access

Excerpt

Recombinant human growth hormone (GH) has been available now for almost 30 years to use as replacement therapy in children and adults suffering from GH deficiency (GHD). One of the early recognized targets for the beneficial effects of GH replacement therapy was the cardiovascular system. GHD affects the cardiovascular system on many levels. Lack of GH results in direct effects on the heart including decreased ventricular mass and cardiac output, reduced exercise capacity and impairment of both diastolic and systolic function (for review see [1]). …
Literature
1.
J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system—an update on a topic at heart. Endocrine 48(1), 25–35 (2015)CrossRefPubMed
2.
R. Böger, C. Skamira, S. Bode-Böger, G. Brabant, A. von zur Mühlen, J. Frölich, Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. 98, 2706–2713 (1996)CrossRefPubMedPubMedCentral
3.
Å. Tivesten, A. Barlind, K. Caidahl, N. Klintland, A. Cittadini, C. Ohlsson, J. Isgaard, Growth hormone-induced decreased blood pressure is associated with increased mRNA levels of the vascular smooth muscle KATP. J. Endocrinol. 183, 195–202 (2004)CrossRefPubMed
4.
J.-O. Johansson, J. Fowelin, K. Landin, I. Lager, B.-Å. Bengtsson, Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126–1129 (1995)CrossRefPubMed
5.
F. Hew, M. Koschmann, M. Christopher, C. Rantzau, A. Vaag, G. Ward, H. Beck-Nielsen, F. Alford, Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. 81, 555–564 (1996)PubMed
6.
W. Drake, S. Howell, J. Monson, S. Shalet, Optimizing GH therapy in adults and children. Endocr. Rev. 22, 425–450 (2001)CrossRefPubMed
7.
J.-O. Johansson, K. Landin, L. Tengborn, T. Rosén, B.-Å. Bengtsson, High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 14, 434–437 (1994)CrossRefPubMed
8.
Y. Sverrisdóttir, M. Elam, B.-Å. Bengtsson, G. Johannsson, Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J. Clin. Endocrinol. Metab. 83, 1881–1885 (1998)PubMed
9.
C. Gazzaruso, M. Gola, I. Karamouzis, R. Giubbini, A. Giustina, Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update. J. Clin. Endocrinol. Metab. 99(1), 18–29 (2014)CrossRefPubMed
10.
M. Boschetti, S. Agosti, V. Albanese, L. Casalino, C. Teti, G. P. Bezante, C. Brunelli, M. Albertelli, D. Ferone, One year GH replacement therapy reduces early cardiac TOD (Target Organ Damage) in adult GHD patients. Endocrine (2016). doi:10.​1007/​s12020-016-0951-4
Metadata
Title
Growth hormone and the heart in growth hormone deficiency—what have we learned so far?
Authors
Jörgen Isgaard
Antonio Cittadini
Publication date
01-02-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1206-0

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue

Original Article

Left ventricular geometry and 24-h blood pressure profile in Cushing’s syndrome

Original Article

Vitamin D receptor gene polymorphisms/haplotypes and serum 25(OH)D3 levels in Hashimoto’s thyroiditis

Original Article

Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care

Endocrine Imaging

Idiopathic hypophosphatemic osteomalacia: recurrent pseudofracture of the proximal femur in a 65-year-old man

Endocrine Genetics/Epigenetics

Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas

Meta-Analysis

Insufficient documentation for clinical efficacy of selenium supplementation in chronic autoimmune thyroiditis, based on a systematic review and meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits